Cytokines in autoimmune bullous skin diseases. Epiphenomena or contribution to pathogenesis?

Giornale Italiano di Dermatologia e Venereologia

Volumn 144, Issue 4, 2009, Pages 339-349

  Ludwig, R J ^a   Schmidt, E ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cytokines; Interleukins; Pemphigoid, bullous; Pemphigus; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CLOBETASOL PROPIONATE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DAPSONE; ETANERCEPT; ETRETIN; GLUCOCORTICOID; GOLIMUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; ISIS 104838; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG WITHDRAWAL; HERPES ZOSTER; HUMAN; IGA PEMPHIGUS; INFLAMMATORY DISEASE; MUCOUS MEMBRANE PEMPHIGOID; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; PSORIASIS; REVIEW; SIDE EFFECT;

EID: 72249104893     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Zillikens D. Autoimmune bullous skin diseases. In: Burgdorf WHC, Plewig G, Wolff HH, Landthaler M, editors. Braun-Falco's Dermatology. 3rd ed. Heidelberg: Springer; 2009. p. 641-670
2. Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005;366:61-73.
3. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007;33:67-77.
4. Nguyen VT, Ndoye A, Shultz LD, Pittelkow MR, Grando SA. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000;106:1467-1479 (Pubitemid 32038585)
5. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992;90:919-926
6. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994;94:59-67. (Pubitemid 24218077)
7. Waschke J. The desmosome and pemphigus. Histochem Cell Biol 2008;130:21-54.
8. Anhalt GJ, Till GO, Diaz LA, Labib RS, Patel HP, Eaglstein NF. Defining the role of complement in experimental pemphigus vulgaris in mice. J Immunol 1986;137:2835-2840
9. Liu Z, Giudice GJ, Swartz SJ, Fairley JA, Till GO, Troy JL, et al. The role of complement in experimental bullous pemphigoid. J Clin Invest 1995;95:1539-1544
10. Sitaru C, Schmidt E, Petermann S, Munteanu LS, Brocker EB, Zillikens D. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol 2002;118:664-671 (Pubitemid 34309987)
11. Chen R, Fairley JA, Zhao ML, Giudice GJ, Zillikens D, Diaz LA, et al. Macrophages, but not T and B lymphocytes, are critical for subepidermal blister formation in experimental bullous pemphigoid: macrophage-mediated neutrophil infiltration depends on mast cell activation. J Immunol 2002;169:3987-3992
12. Liu Z, Shapiro SD, Zhou X, Twining SS, Senior RM, Giudice GJ, et al. A critical role for neutrophil elastase in experimental bullous pemphigoid. J Clin Invest 2000;105:113-123 (Pubitemid 30036393)
13. Liu Z, Shipley JM, Vu TH, Zhou X, Diaz LA, Werb Z, et al. Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med 1998;188:475-482 (Pubitemid 28369137)
14. Durum SK, Oppenheim JJ, Feldmann M. Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense. 2nd edition ed. Academic Press Inc; 2000.
15. Feldmann M, Maini SR. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008;223:7-19.
16. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 1994;91:1198-1205
17. Feldman M, Taylor P, Paleolog E, Brennan FM, Maini RN. Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc 1998;30:4126-4127 (Pubitemid 29013179)
18. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-390 (Pubitemid 30487495)
19. Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC et al. A pilot study of adalimumab in infliximab-allergic patients. Infiamm Bowel Dis 2004;10:333-338 (Pubitemid 39029174)
20. Carswell EA, Old U, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-3670
21. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984;312:724-729
22. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN. The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 2004;18:59-80. (Pubitemid 38324659)
23. Xu H, Sethi JK, Hotamisligil GS. Transmembrane tumor necrosis factor TNF)-alpha inhibits adipocyte differentiation by selectively activating TNF receptor 1. J Biol Chem 1999;274:26287-26295 (Pubitemid 129520059)
24. Perez C, Albert I, DeFay K, Zachariades N, Gooding L, Kriegler M. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 1990;63:251-258
25. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110 (Pubitemid 24317629)
26. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R. Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol 1995;155:5038-5045
27. den Broeder AA, Joosten LA, Saxne T, Heinegard D, Fenner H, Miltenburg AM et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-318
28. D'Auria L, Bonifati C, Mussi A, D'Agosto G, De SC, Giacalone B et al. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997;8:383-387
29. Ameglio F, D'Auria L, Cordiali-Fei P, Trento E, D'Agosto G, Mastroianni A et al. Anti-intercellular substance antibody log titres are correlated with serum concentrations of interleukin-6, interleukin-15 and tumor necrosis factor-alpha in patients with Pemphigus vulgaris relationships with peripheral blood neutrophil counts, disease severity and duration and patients' age. J Biol Regul Homeost Agents 1999;13:220-224
30. Alecu M, Alecu S, Coman G, Galatescu E, Ursaciuc C. ICAM-1, ELAM-1, TNF-alpha and IL-6 in serum and blister liquid of pemphigus vulgaris patients. Roum Arch Microbiol Immunol 1999;58:121-130
31. Narbutt J, Lukamowicz J, Bogaczewicz J, Sysa-Jedrzejowska A, Torzecka JD, Lesiak A. Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediators Inflamm 2008;2008:875394.
32. Feliciani C, Toto P, Amerio P, Pour SM, Coscione G, Shivji G et al. In vitro and in vivo expression of interleukin-1 alpha and tumor necrosis factor-alpha mRNA in pemphigus vulgaris: interleukin-1 alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000;114:71-77
33. Lopez-Robles E, Avalos-Diaz E, Vega-Memije E, Hojyo-Tomoka T, Villalobos R, Fraire S, et al. TNFαlpha and IL-6 are mediators in the blistering process of pemphigus. Int J Dermatol 2001;40:185-188 (Pubitemid 32586277)
34. Morioka S, Lazarus GS, Jensen PJ. Involvement of urokinase-type plasminogen activator in acantholysis induced by pemphigus IgG. J Invest Dermatol 1987;89:474-477
35. Wilkinson JE, Smith CA, Suter MM, Falchek W, Lewis RM. Role of plasminogen activator in pemphigus vulgaris. Am J Pathol 1989;134:561-569 (Pubitemid 19082850)
36. Feliciani C, Toto P, Wang B, Sauder DN, Amerio P, Tulli A. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 2003;12:466-471
37. Mahoney MG, Wang ZH, Stanley JR. Pemphigus vulgaris and pemphigus foliaceus antibodies are pathogenic in plasminogen activator knockout mice. J Invest Dermatol 1999;113:22-25
38. D'Auria L, Mussi A, Bonifati C, Mastroianni A, Giacalone B, Ameglio F. Increased serum IL-6, TNF-alpha and IL-10 levels in patients with bullous pemphigoid: relationships with disease activity. J Eur Acad Dermatol Venereol 1999;12:11-15 (Pubitemid 29132980)
39. Lee SJ, Li Z, Sherman B, Foster CS. Serum levels of tumor necrosis factor-alpha and interleukin-6 in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci 1993;34:3522-3525 (Pubitemid 24011987)
40. Rhodes LE, Hashim IA, McLaughlin PJ, Friedmann PS. Blister fluid cytokines in cutaneous inflammatory bullous disorders. Acta Derm Venereol 1999;79:288-290
41. Cordero CM, Yilmaz T, Foster CS. Tumour necrosis factor-alpha in conjunctivae affected by ocular cicatricial pemphigoid. Acta Ophthalmol Scand 2007;85:753-755 (Pubitemid 47616792)
42. Saw VP, Dart RJ, Galatowicz G, Daniels JT, Dart J, Calder VL. Tumour Necrosis Factor-{alpha) in Ocular Mucous Membrane Pemphigoid and its effect on Conjunctival Fibroblasts. Invest Ophthalmol Vis Sci 2009 Jun 3. [Epub ahead of print]
43. Stausbol-Gron B, Deleuran M, Sommer HE, Kragballe K. Development of bullous pemphigoid during treatment of psoriasis with adalimumab. Clin Exp Dermatol 2009 May 5. [Epub ahead of print]
44. Schön M, Ludwig RJ. Leukocyte trafficking to inflamed skin - molecular mechanisms and implications for therapeutic target mole- cules. Expert Opin Ther Targets 2005;9:225-243 (Pubitemid 40613865)
45. Bieber K, Sun S, Ishii N, Kasperkiewicz M, Schmidt E, Hirose M, et al. Animal models for autoimmune bullous dermatoses. Exp Dermatol 2009. In press.
46. Chiriac MT, Roesler J, Sindrilaru A, Scharffetter-Kochanek K, Zillikens D, Sitaru C. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol 2007;212: 56-65.
47. Liu Z, Zhao M, Li N, Diaz LA, Mayadas TN. Differential roles for beta2 integrins in experimental autoimmune bullous pemphigoid. Blood 2006;107:1063-1069 (Pubitemid 43156306)
48. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol 2002;14:117-122
49. Braddock M, Quinn A. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat Rev Drug Discov 2004;3:330-339 (Pubitemid 38499760)
50. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G. Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 1995;270:13757-13765
51. Liege S, Laye S, Li KS, Moze E, Neveu PJ. Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta. J Neuroimmunol 2000;110:134-139 (Pubitemid 30750465)
52. Hallegua DS, Weisman MH. Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases. Ann Rheum Dis 2002;61:960-967 (Pubitemid 35221682)
53. Opal SM, Fisher CJ, Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997;25:1115-1124 (Pubitemid 27310249)
54. Fisher CJ, Jr., Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994;271:1836-1843
55. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum 1996;39:1092-101.
56. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-2204
57. Anakinra - open studies at ClinicalTrials.gov. http://clinicaltrialsgov/ ct2/results?term=anakinra&recr=Open2009, July 14
58. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1 beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-89
59. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-2425
60. Arostegui JI, Aldea A, Modesto C, Rua MJ, Arguelles F, Gonzalez-Ensenat MA et al. Clinical and genetic heterogeneity among Spanish patients with recurrent autoinflammatory syndromes associated with the CIAS1/PYPAF1/NALP3 gene. Arthritis Rheum 2004;50:4045-4050 (Pubitemid 39643954)
61. Canakinumab - open studies at ClinicalTrials.gov. http:// clinicaltrialsgov/ct2/results?term=canakinumab 2009, July 12
62. Grando SA, Glukhenky BT, Drannik GN, Epshtein EV, Kostromin AP, Korostash TA. Mediators of inflammation in blister fluids from patients with pemphigus vulgaris and bullous pemphigoid. Arch Dermatol 1989;125:925-930
63. Keskin DB, Stern JN, Fridkis-Hareli M, Razzaque AA. Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy. Cytokine 2008;41:315-321
64. Bhol KC, Desai A, Kumari S, Colon JE, Ahmed AR. Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production. Clin Immunol 2001;100:172-180 (Pubitemid 32703422)
65. Ameglio F, D'Auria L, Bonifati C, Ferraro C, Mastroianni A, Giacalone B. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: Relationships with disease intensity. Br J Dermatol 1998;138:611-614 (Pubitemid 28212243)
66. Schmidt E, Mittnacht A, Schomig H, Dummer R, Brocker EB, Zillikens D. Detection of IL-1 alpha, IL-1 beta and IL-1 receptor antagonist in blister fluid of bullous pemphigoid. J Dermatol Sci 1996;11:142-147 (Pubitemid 2617635)
67. Chang YT, Liu HN, Yu CW, Lin MW, Huang CH, Chen CC, et al. Cytokine gene polymorphisms in bullous pemphigoid in a Chinese population. Br J Dermatol 2006;154:79-84. (Pubitemid 43381324)
68. Kishimoto T, Hibi M, Murakami M, Narazaki M, Saito M, Taga T. The molecular biology of interleukin 6 and its receptor. Ciba Found Symp 1992;167:5-16.
69. Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-253
70. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-3150
71. Rorito S, Magrini L. Autoimmune features in atherosclerotic ischemic cardiomyopathy. Allerg Immunol (Paris) 1992;24:336-341
72. Open studies with tocilizumab on ClinicalTriaIs.gov. http:// clinicaltrialsgov/ct2/results?term=tocilizumab&recr=Open&show-flds=Y, 2009 July 12
73. Nousari HC, Kimyai-Asadi A, Anhalt GJ. Elevated serum levels of interleukin-6 in paraneoplastic pemphigus. J Invest Dermatol 1999;112:396-398
74. Scheinecker C, Smolen J, Yasothan U, Stoll J, Kirkpatrick P. Tocilizumab. Nat Rev Drug Discov 2009;8:273-274
75. Schmidt E, Bastian B, Dummer R, Tony HP, Brocker EB, Zillikens D. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid. Arch Dermatol Res 1996;288:353-357
76. Inaoki M, Takehara K. Increased serum levels of interleukin (IL)-5, IL-6 and IL-8 in bullous pemphigoid. J Dermatol Sci 1998;16:152-7.
77. Schmidt E, Reimer S, Kruse N, Jainta S, Brocker EB, Marinkovich MP et al. Autoantibodies to BP180 associated with bullous pemphigoid release interleukin-6 and interleukin-8 from cultured human keratinocytes. J Invest Dermatol 2000;115:842-848
78. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002;346:321-327 (Pubitemid 34438839)
79. Joly P, Roujeau JC, Benichou J, Delaporte E, D'Incan M, Dreno B, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009;129:1681-1687
80. Choy EH, Hazleman B, Smith M, Moss K, Lisi L, Scott DG et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 2002;41: 1133-1137 (Pubitemid 35203540)
81. Melmed GY, Targan SR, Yasothan U, Hanicq D, Kirkpatrick P. Certolizumab pegol. Nat Rev Drug Discov 2008;7:641-642
82. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ et al. Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J Pharmacol Exp Ther 2002;303:1334-1343
83. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-396 (Pubitemid 46294717)
84. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-986
85. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004;74:245-247 (Pubitemid 39462890)
86. Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005;141:680-682
87. Gubinelli E, Bergamo F, Didona B, Annessi G, Atzori F, Raskovic D. Pemphigus foliaceus treated with etanercept. J Am Acad Dermatol 2006;55:1107-1108
88. Pardo J, Mercader P, Mahiques L, Sanchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005;153:222-223 (Pubitemid 41044564)
89. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005;153:448-449 (Pubitemid 41228454)
90. Howell SM, Bessinger GT, Altman CE, Belnap CM. Rapid response of IgA pemphigus of the subcorneal pustular dermatosis subtype to treatment with adalimumab and mycophenolate mofetil. J Am Acad Dermatol 2005;53:541-543
91. Sacher C, Rubbert A, Konig C, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002;46:113-115 (Pubitemid 34073488)
92. Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexsiting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2005;54:S121-S122. (Pubitemid 43243484)
93. Canizares MJ, Smith DI, Conners MS, Maverick KJ, Heffernan MP. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol 2006;142:1457-1461 (Pubitemid 44790639)
94. Prey S, Robert PY, Drouet M, Sparsa A, Roux C, Bonnetblanc JM et al. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol 2007;87:74-75
95. John H, Whallett A, Quinlan M. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha. Eye 2007;21:1434-1435 (Pubitemid 350066484)
96. Saraceno R, Citarella L, Spallone G, Chimenti S. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy. Clin Exp Dermatol 2008;33:154-155 (Pubitemid 351197207)
97. Heffernan MP, Bentley DD. Successful treatment of mucous membrane pemphigoid with infliximab. Arch Dermatol 2006;142:1268-70.